The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol

By Procyshyn R.M.   Tsai G.   Wasan K.M.  

European Neuropsychopharmacology, Vol. 13, Iss. 1, 2003-01 ,pp. : 33-37

Elsevier

Access to resources Recommend Favorite

Differences in human phospholipid transfer protein activity following incubation of Fungizone® compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma

By Henderson Ryan J.   Leon Carlos G.   Wasan Kishor M.  

Drug Development and Industrial Pharmacy, Vol. 35, Iss. 9, 2009-09 ,pp. : 1139-1146

Informa Healthcare

Access to resources Recommend Favorite

Beneficial effects of cordycepin on metabolic profiles of liver and plasma from hyperlipidemic hamsters

By Sun Yang  

Journal of Asian Natural Products Research, Vol. 13, Iss. 6, 2011-06 ,pp. : 534-546

Taylor & Francis Ltd

Access to resources Recommend Favorite

Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals

By Okamoto H.   Iwamoto Y.   Maki M.   Sotani T.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 466, Iss. 1, 2003-04 ,pp. : 147-154

Elsevier

Access to resources Recommend Favorite

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents

By  

Pharmacology Research & Perspectives, Vol. 6, Iss. 1, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite